These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 291474)

  • 1. The gingival platinum line: a new finding following cis-dichlorodiammine platinum (II) treatment.
    Ettinger LJ; Freeman AI
    Cancer; 1979 Nov; 44(5):1882-4. PubMed ID: 291474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. cis-Dichlorodiammineplatinum (II) in advanced osteogenic sarcoma.
    Ochs JJ; Freeman AI; Douglass HO; Higby DS; Mindell ER; Sinks LF
    Cancer Treat Rep; 1978 Feb; 62(2):239-45. PubMed ID: 346212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. cis-Dichlorodiammineplatinum(II) in childhood cancer.
    Freeman AI; Ettinger LJ; Brecher ML
    Cancer Treat Rep; 1979; 63(9-10):1615-20. PubMed ID: 291483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II clinical trial of cis-dichlorodiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer.
    Kolarić K; Roth A
    Cancer Chemother Pharmacol; 1983; 11(2):108-12. PubMed ID: 6685001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity, induction of cross-resistance, and nephrotoxicity of a new platinum analogue, cis-1,1-diaminomethylcyclohexaneplatinum(II) sulfate, and of cis-diamminedichloroplatinum(II) in an immunocytoma model in the LOU/M rat.
    de Jong WH; Steerenberg PA; Vos JG; Bulten EJ; Verbeek F; Kruizinga W; Ruitenberg EJ
    Cancer Res; 1983 Oct; 43(10):4927-34. PubMed ID: 6683993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized clinical trial comparing radiation therapy v radiation therapy plus cis-dichlorodiammine platinum (II) in the treatment of locally advanced non-small cell lung cancer.
    Soresi E; Clerici M; Grilli R; Borghini U; Zucali R; Leoni M; Botturi M; Vergari C; Luporini G; Scoccia S
    Semin Oncol; 1988 Dec; 15(6 Suppl 7):20-5. PubMed ID: 2851172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Acute and subacute toxicity of antineoplastic Pt(II) and Pt(IV) coordination compounds in laboratory rodents].
    Härtl A; Güttner J; Horn U; Jelinek F; Stöckel U; Schröer HP; Hoffmann H
    Arch Geschwulstforsch; 1989; 59(4):239-44. PubMed ID: 2640563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-fluorouracil and cis-platinum in the treatment of refractory solid tumors: a pediatric oncology group phase I-II study.
    Land VJ; Dyment PG; Starling K; Strandjord SE; Chan R
    Med Pediatr Oncol; 1981; 9(3):289-91. PubMed ID: 6941070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced cellular uptake of cis-dichlorodiammine-platinum by benzaldehyde.
    Dornish JM; Melvik JE; Pettersen EO
    Anticancer Res; 1986; 6(4):583-8. PubMed ID: 3752939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atopic hypersensitivity to cis-dichlorodiammineplatinum(II) and other platinum complexes.
    Khan A; Hill JM; Grater W; Loeb E; MacLellan A; Hill N
    Cancer Res; 1975 Oct; 35(10):2766-70. PubMed ID: 50881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacology and pharmacokinetics of cis-platinum and analogs.
    Ribaud P; Gouveia J; Bonnay M; Mathe G
    Cancer Treat Rep; 1981; 65 Suppl 3():97-105. PubMed ID: 7049371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral neuropathy as a complication of cis-dichlorodiammineplatinum(II) treatment: a case report.
    Kedar A; Cohen ME; Freeman AI
    Cancer Treat Rep; 1978 May; 62(5):819-21. PubMed ID: 207427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute nephrotoxicity following cis-dichlorodiammine-platinum.
    Bitran JD; Desser RK; Billings AA; Kozloff MF; Shapiro CM
    Cancer; 1982 May; 49(9):1784-8. PubMed ID: 7200396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice.
    Schabel FM; Trader MW; Laster WR; Corbett TH; Griswold DP
    Cancer Treat Rep; 1979; 63(9-10):1459-73. PubMed ID: 291480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential toxicity of cis- and trans-diamminedichloroplatinum(II) toward mammalian cells: lack of influence of any difference in the rates of loss of their DNA-bound adducts.
    Roberts JJ; Friedlos F
    Cancer Res; 1987 Jan; 47(1):31-6. PubMed ID: 3791217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cis-dichlorodiammineplatinum(II) alone and combined with DTIC for treatment of disseminated malignant melanoma.
    Goodnight JE; Moseley HS; Eilber FR; Sarna G; Morton DL
    Cancer Treat Rep; 1979; 63(11-12):2005-7. PubMed ID: 393385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic study of Cis-dichlorodiammine platinum II, in children after rapid infusion.
    Cano JP; Catalin J; Rigault JP; Bues-Charbit M; Placidi M; Raybaud C; Bernard JL
    Biomedicine; 1981 Dec; 34(3):146-53. PubMed ID: 7199945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W; Chaney SG
    Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclic AMP levels of C6 glioma cells treated with cis-dichlorodiammine platinum (cis-DDP).
    Folbergrová J; Lisá V; Drobník J; Mares V
    Neoplasma; 1987; 34(1):3-13. PubMed ID: 3031519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW; van den Berg H; van Dalen EC
    Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.